Growth and maturation patterns were complicated by multiple factors including the degree of SS and/or CPP, the presence or absence of therapeutic intervention, the age at the start of therapeutic intervention (eg, the start of GH therapy before or after pubertal entry and that of GnRHa therapy before or after menarche), and the variable dosages and durations of GH and GnRHa therapy. This evidence concerns the gene GH1 and synovial sarcoma.